Tyler Bold, MD, PhD

Assistant Professor of Medicine, Division of Infectious Diseases and International Medicine

Tyler  Bold

Contact Info

Mailing Address:
2101 6th Street SE
MC 2641 Room 2-118
WMBB Building
Minneapolis, MN 55455

Administrative Assistant Name
Becca Johnson

Administrative Phone
612-624-9996

Administrative Email
joh07913@umn.edu

Administrative Fax Number
612-625-4410

Medical School, New York University, New York, NY

Residency, Brigham and Women's Hospital, Boston, MA

Fellowship, Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA

PhD, New York University, New York, NY

Summary

Dr. Bold is a physician-scientist, trained in the clinical subspecialty practice of infectious diseases, and laboratory based investigations of microbiology and immunology. His clinical interests regard the care of immune-compromised patients being treated for cancer or undergoing transplantation. His lab in the Center for Immunology is focused on advancing understanding of how the adaptive immune system combats infection with Mycobacterium tuberculosis, the bacterial pathogen responsible for human TB.

Expertise

  • Tuberculosis
  • Immunology
  • Transplant Infectious Diseases

Research

Research Summary/Interests

Dr. Bold is a physician-scientist, trained in the clinical practice of infectious diseases and laboratory based investigations of microbiology and immunology. His clinical interests regard the care of immune-compromised patients being treated for cancer or undergoing transplantation. His lab in the Center for Immunology is focused on advancing understanding of how the immune system combats infection with Mycobacterium tuberculosis, the bacterial pathogen responsible for human TB, and SARS-CoV-2, the virus that causes COVID-19.

Publications

  • Vedula RS, Cheng MP, Ronayne CE, Farmakiotis D, Ho VT, Koo S, Marty FM, Lindsley RC, Bold TD. Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Adv. 2021 Jan 12;5(1):54-60. doi: 10.1182/bloodadvances.2020002854. PMID: 33570623; PMCID: PMC7805332.
  • Fiege JK, Thiede JM, Nanda HA, Matchett WE, Moore PJ, Montanari NR, Thielen BK, Daniel J, Stanley E, Hunter RC, Menachery VD, Shen SS, Bold TD, Langlois RA. Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. PLoS Pathog. 2021 Jan 28;17(1):e1009292. doi: 10.1371/journal.ppat.1009292. PMID: 33507952; PMCID: PMC7872261.
  • Thiede JM, Gress AR, Libby SD, Ronayne CE, Matchett WE, Noren B, Billings JL, Menachery VD, Langlois RA, Kline S, Bold TD. Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial. J Infect Dis. 2021 Apr 23;223(8):1339-1344. doi: 10.1093/infdis/jiab035. PMID: 33476387; PMCID: PMC7928927.
  • Martyn EM, Bangdiwala AS, Kagimu E, Rutakingirwa MK, Kasibante J, Okirwoth M, Stead G, Wadda V, Pullen MF, Bold TD, Meya DB, Boulware DR, Bahr NC, Cresswell FV. Cerebrospinal fluid bacillary load by Xpert MTB/RIF Ultra PCR Cycle Threshold value predicts two-week mortality in HIV-associated tuberculous meningitis. Clin Infect Dis. 2020 Sep 28:ciaa1444. doi: 10.1093/cid/ciaa1444. Epub ahead of print. PMID: 32986792.
  • Gniadek TJ, Thiede JM, Matchett WE, Gress AR, Pape KA, Fiege JK, Jenkins MK, Menachery VD, Langlois RA, Bold TD. SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease. Transfusion. 2021 Jan;61(1):17-23. doi: 10.1111/trf.16101. Epub 2020 Oct 2. PMID: 32935872; PMCID: PMC7995753.

Clinical

Board Certifications

  • ABIM

Clinical Interests

Transplant Infectious Diseases